Global Vaccines for the Elderly Market Growth 2026-2032
The global Vaccines for the Elderly market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
United States market for Vaccines for the Elderly is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Vaccines for the Elderly is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Vaccines for the Elderly is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Vaccines for the Elderly players cover Pfizer, GSK, Merck, CSL, Sanofi, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Vaccines for the Elderly Industry Forecast” looks at past sales and reviews total world Vaccines for the Elderly sales in 2025, providing a comprehensive analysis by region and market sector of projected Vaccines for the Elderly sales for 2026 through 2032. With Vaccines for the Elderly sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Vaccines for the Elderly industry.
This Insight Report provides a comprehensive analysis of the global Vaccines for the Elderly landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vaccines for the Elderly portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Vaccines for the Elderly market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vaccines for the Elderly and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vaccines for the Elderly.
This report presents a comprehensive overview, market shares, and growth opportunities of Vaccines for the Elderly market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
United States market for Vaccines for the Elderly is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Vaccines for the Elderly is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Vaccines for the Elderly is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Vaccines for the Elderly players cover Pfizer, GSK, Merck, CSL, Sanofi, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Vaccines for the Elderly Industry Forecast” looks at past sales and reviews total world Vaccines for the Elderly sales in 2025, providing a comprehensive analysis by region and market sector of projected Vaccines for the Elderly sales for 2026 through 2032. With Vaccines for the Elderly sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Vaccines for the Elderly industry.
This Insight Report provides a comprehensive analysis of the global Vaccines for the Elderly landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vaccines for the Elderly portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Vaccines for the Elderly market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vaccines for the Elderly and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vaccines for the Elderly.
This report presents a comprehensive overview, market shares, and growth opportunities of Vaccines for the Elderly market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Flu Vaccine
- Respiratory Syncytial Virus (RSV) Vaccine
- Recombinant Herpes Zoster Vaccine
- 23-Valent Pneumococcal Polysaccharide Vaccine
- Others
- Hospital
- Clinic
- Public Health Agency
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- GSK
- Merck
- CSL
- Sanofi
- AstraZeneca
- Hualan Bio
- Sinovac
- Kangtai Bio
- CDIBP
- Walvax
- What is the 10-year outlook for the global Vaccines for the Elderly market?
- What factors are driving Vaccines for the Elderly market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Vaccines for the Elderly market opportunities vary by end market size?
- How does Vaccines for the Elderly break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Vaccines for the Elderly Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Vaccines for the Elderly by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Vaccines for the Elderly by Country/Region, 2021, 2025 & 2032
2.2 Vaccines for the Elderly Segment by Type
2.2.1 Flu Vaccine
2.2.2 Respiratory Syncytial Virus (RSV) Vaccine
2.2.3 Recombinant Herpes Zoster Vaccine
2.2.4 23-Valent Pneumococcal Polysaccharide Vaccine
2.2.5 Others
2.2.6 Vaccines for the Elderly Sales by Type
2.2.6.1 Global Vaccines for the Elderly Sales Market Share by Type (2021-2026)
2.2.6.2 Global Vaccines for the Elderly Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global Vaccines for the Elderly Sale Price by Type (2021-2026)
2.3 Vaccines for the Elderly Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Public Health Agency
2.3.4 Others
2.3.5 Vaccines for the Elderly Sales by Application
2.3.5.1 Global Vaccines for the Elderly Sale Market Share by Application (2021-2026)
2.3.5.2 Global Vaccines for the Elderly Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Vaccines for the Elderly Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Vaccines for the Elderly Breakdown Data by Company
3.1.1 Global Vaccines for the Elderly Annual Sales by Company (2021-2026)
3.1.2 Global Vaccines for the Elderly Sales Market Share by Company (2021-2026)
3.2 Global Vaccines for the Elderly Annual Revenue by Company (2021-2026)
3.2.1 Global Vaccines for the Elderly Revenue by Company (2021-2026)
3.2.2 Global Vaccines for the Elderly Revenue Market Share by Company (2021-2026)
3.3 Global Vaccines for the Elderly Sale Price by Company
3.4 Key Manufacturers Vaccines for the Elderly Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Vaccines for the Elderly Product Location Distribution
3.4.2 Players Vaccines for the Elderly Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR VACCINES FOR THE ELDERLY BY GEOGRAPHIC REGION
4.1 World Historic Vaccines for the Elderly Market Size by Geographic Region (2021-2026)
4.1.1 Global Vaccines for the Elderly Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Vaccines for the Elderly Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Vaccines for the Elderly Market Size by Country/Region (2021-2026)
4.2.1 Global Vaccines for the Elderly Annual Sales by Country/Region (2021-2026)
4.2.2 Global Vaccines for the Elderly Annual Revenue by Country/Region (2021-2026)
4.3 Americas Vaccines for the Elderly Sales Growth
4.4 APAC Vaccines for the Elderly Sales Growth
4.5 Europe Vaccines for the Elderly Sales Growth
4.6 Middle East & Africa Vaccines for the Elderly Sales Growth
5 AMERICAS
5.1 Americas Vaccines for the Elderly Sales by Country
5.1.1 Americas Vaccines for the Elderly Sales by Country (2021-2026)
5.1.2 Americas Vaccines for the Elderly Revenue by Country (2021-2026)
5.2 Americas Vaccines for the Elderly Sales by Type (2021-2026)
5.3 Americas Vaccines for the Elderly Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Vaccines for the Elderly Sales by Region
6.1.1 APAC Vaccines for the Elderly Sales by Region (2021-2026)
6.1.2 APAC Vaccines for the Elderly Revenue by Region (2021-2026)
6.2 APAC Vaccines for the Elderly Sales by Type (2021-2026)
6.3 APAC Vaccines for the Elderly Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Vaccines for the Elderly by Country
7.1.1 Europe Vaccines for the Elderly Sales by Country (2021-2026)
7.1.2 Europe Vaccines for the Elderly Revenue by Country (2021-2026)
7.2 Europe Vaccines for the Elderly Sales by Type (2021-2026)
7.3 Europe Vaccines for the Elderly Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Vaccines for the Elderly by Country
8.1.1 Middle East & Africa Vaccines for the Elderly Sales by Country (2021-2026)
8.1.2 Middle East & Africa Vaccines for the Elderly Revenue by Country (2021-2026)
8.2 Middle East & Africa Vaccines for the Elderly Sales by Type (2021-2026)
8.3 Middle East & Africa Vaccines for the Elderly Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Vaccines for the Elderly
10.3 Manufacturing Process Analysis of Vaccines for the Elderly
10.4 Industry Chain Structure of Vaccines for the Elderly
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Vaccines for the Elderly Distributors
11.3 Vaccines for the Elderly Customer
12 WORLD FORECAST REVIEW FOR VACCINES FOR THE ELDERLY BY GEOGRAPHIC REGION
12.1 Global Vaccines for the Elderly Market Size Forecast by Region
12.1.1 Global Vaccines for the Elderly Forecast by Region (2027-2032)
12.1.2 Global Vaccines for the Elderly Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Vaccines for the Elderly Forecast by Type (2027-2032)
12.7 Global Vaccines for the Elderly Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Vaccines for the Elderly Product Portfolios and Specifications
13.1.3 Pfizer Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Vaccines for the Elderly Product Portfolios and Specifications
13.2.3 GSK Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Merck
13.3.1 Merck Company Information
13.3.2 Merck Vaccines for the Elderly Product Portfolios and Specifications
13.3.3 Merck Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Merck Main Business Overview
13.3.5 Merck Latest Developments
13.4 CSL
13.4.1 CSL Company Information
13.4.2 CSL Vaccines for the Elderly Product Portfolios and Specifications
13.4.3 CSL Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 CSL Main Business Overview
13.4.5 CSL Latest Developments
13.5 Sanofi
13.5.1 Sanofi Company Information
13.5.2 Sanofi Vaccines for the Elderly Product Portfolios and Specifications
13.5.3 Sanofi Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sanofi Main Business Overview
13.5.5 Sanofi Latest Developments
13.6 AstraZeneca
13.6.1 AstraZeneca Company Information
13.6.2 AstraZeneca Vaccines for the Elderly Product Portfolios and Specifications
13.6.3 AstraZeneca Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 AstraZeneca Main Business Overview
13.6.5 AstraZeneca Latest Developments
13.7 Hualan Bio
13.7.1 Hualan Bio Company Information
13.7.2 Hualan Bio Vaccines for the Elderly Product Portfolios and Specifications
13.7.3 Hualan Bio Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Hualan Bio Main Business Overview
13.7.5 Hualan Bio Latest Developments
13.8 Sinovac
13.8.1 Sinovac Company Information
13.8.2 Sinovac Vaccines for the Elderly Product Portfolios and Specifications
13.8.3 Sinovac Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Sinovac Main Business Overview
13.8.5 Sinovac Latest Developments
13.9 Kangtai Bio
13.9.1 Kangtai Bio Company Information
13.9.2 Kangtai Bio Vaccines for the Elderly Product Portfolios and Specifications
13.9.3 Kangtai Bio Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Kangtai Bio Main Business Overview
13.9.5 Kangtai Bio Latest Developments
13.10 CDIBP
13.10.1 CDIBP Company Information
13.10.2 CDIBP Vaccines for the Elderly Product Portfolios and Specifications
13.10.3 CDIBP Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 CDIBP Main Business Overview
13.10.5 CDIBP Latest Developments
13.11 Walvax
13.11.1 Walvax Company Information
13.11.2 Walvax Vaccines for the Elderly Product Portfolios and Specifications
13.11.3 Walvax Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Walvax Main Business Overview
13.11.5 Walvax Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Vaccines for the Elderly Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Vaccines for the Elderly by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Vaccines for the Elderly by Country/Region, 2021, 2025 & 2032
2.2 Vaccines for the Elderly Segment by Type
2.2.1 Flu Vaccine
2.2.2 Respiratory Syncytial Virus (RSV) Vaccine
2.2.3 Recombinant Herpes Zoster Vaccine
2.2.4 23-Valent Pneumococcal Polysaccharide Vaccine
2.2.5 Others
2.2.6 Vaccines for the Elderly Sales by Type
2.2.6.1 Global Vaccines for the Elderly Sales Market Share by Type (2021-2026)
2.2.6.2 Global Vaccines for the Elderly Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global Vaccines for the Elderly Sale Price by Type (2021-2026)
2.3 Vaccines for the Elderly Segment by Application
2.3.1 Hospital
2.3.2 Clinic
2.3.3 Public Health Agency
2.3.4 Others
2.3.5 Vaccines for the Elderly Sales by Application
2.3.5.1 Global Vaccines for the Elderly Sale Market Share by Application (2021-2026)
2.3.5.2 Global Vaccines for the Elderly Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Vaccines for the Elderly Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Vaccines for the Elderly Breakdown Data by Company
3.1.1 Global Vaccines for the Elderly Annual Sales by Company (2021-2026)
3.1.2 Global Vaccines for the Elderly Sales Market Share by Company (2021-2026)
3.2 Global Vaccines for the Elderly Annual Revenue by Company (2021-2026)
3.2.1 Global Vaccines for the Elderly Revenue by Company (2021-2026)
3.2.2 Global Vaccines for the Elderly Revenue Market Share by Company (2021-2026)
3.3 Global Vaccines for the Elderly Sale Price by Company
3.4 Key Manufacturers Vaccines for the Elderly Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Vaccines for the Elderly Product Location Distribution
3.4.2 Players Vaccines for the Elderly Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR VACCINES FOR THE ELDERLY BY GEOGRAPHIC REGION
4.1 World Historic Vaccines for the Elderly Market Size by Geographic Region (2021-2026)
4.1.1 Global Vaccines for the Elderly Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Vaccines for the Elderly Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Vaccines for the Elderly Market Size by Country/Region (2021-2026)
4.2.1 Global Vaccines for the Elderly Annual Sales by Country/Region (2021-2026)
4.2.2 Global Vaccines for the Elderly Annual Revenue by Country/Region (2021-2026)
4.3 Americas Vaccines for the Elderly Sales Growth
4.4 APAC Vaccines for the Elderly Sales Growth
4.5 Europe Vaccines for the Elderly Sales Growth
4.6 Middle East & Africa Vaccines for the Elderly Sales Growth
5 AMERICAS
5.1 Americas Vaccines for the Elderly Sales by Country
5.1.1 Americas Vaccines for the Elderly Sales by Country (2021-2026)
5.1.2 Americas Vaccines for the Elderly Revenue by Country (2021-2026)
5.2 Americas Vaccines for the Elderly Sales by Type (2021-2026)
5.3 Americas Vaccines for the Elderly Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Vaccines for the Elderly Sales by Region
6.1.1 APAC Vaccines for the Elderly Sales by Region (2021-2026)
6.1.2 APAC Vaccines for the Elderly Revenue by Region (2021-2026)
6.2 APAC Vaccines for the Elderly Sales by Type (2021-2026)
6.3 APAC Vaccines for the Elderly Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Vaccines for the Elderly by Country
7.1.1 Europe Vaccines for the Elderly Sales by Country (2021-2026)
7.1.2 Europe Vaccines for the Elderly Revenue by Country (2021-2026)
7.2 Europe Vaccines for the Elderly Sales by Type (2021-2026)
7.3 Europe Vaccines for the Elderly Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Vaccines for the Elderly by Country
8.1.1 Middle East & Africa Vaccines for the Elderly Sales by Country (2021-2026)
8.1.2 Middle East & Africa Vaccines for the Elderly Revenue by Country (2021-2026)
8.2 Middle East & Africa Vaccines for the Elderly Sales by Type (2021-2026)
8.3 Middle East & Africa Vaccines for the Elderly Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Vaccines for the Elderly
10.3 Manufacturing Process Analysis of Vaccines for the Elderly
10.4 Industry Chain Structure of Vaccines for the Elderly
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Vaccines for the Elderly Distributors
11.3 Vaccines for the Elderly Customer
12 WORLD FORECAST REVIEW FOR VACCINES FOR THE ELDERLY BY GEOGRAPHIC REGION
12.1 Global Vaccines for the Elderly Market Size Forecast by Region
12.1.1 Global Vaccines for the Elderly Forecast by Region (2027-2032)
12.1.2 Global Vaccines for the Elderly Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Vaccines for the Elderly Forecast by Type (2027-2032)
12.7 Global Vaccines for the Elderly Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Vaccines for the Elderly Product Portfolios and Specifications
13.1.3 Pfizer Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Vaccines for the Elderly Product Portfolios and Specifications
13.2.3 GSK Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Merck
13.3.1 Merck Company Information
13.3.2 Merck Vaccines for the Elderly Product Portfolios and Specifications
13.3.3 Merck Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Merck Main Business Overview
13.3.5 Merck Latest Developments
13.4 CSL
13.4.1 CSL Company Information
13.4.2 CSL Vaccines for the Elderly Product Portfolios and Specifications
13.4.3 CSL Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 CSL Main Business Overview
13.4.5 CSL Latest Developments
13.5 Sanofi
13.5.1 Sanofi Company Information
13.5.2 Sanofi Vaccines for the Elderly Product Portfolios and Specifications
13.5.3 Sanofi Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sanofi Main Business Overview
13.5.5 Sanofi Latest Developments
13.6 AstraZeneca
13.6.1 AstraZeneca Company Information
13.6.2 AstraZeneca Vaccines for the Elderly Product Portfolios and Specifications
13.6.3 AstraZeneca Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 AstraZeneca Main Business Overview
13.6.5 AstraZeneca Latest Developments
13.7 Hualan Bio
13.7.1 Hualan Bio Company Information
13.7.2 Hualan Bio Vaccines for the Elderly Product Portfolios and Specifications
13.7.3 Hualan Bio Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Hualan Bio Main Business Overview
13.7.5 Hualan Bio Latest Developments
13.8 Sinovac
13.8.1 Sinovac Company Information
13.8.2 Sinovac Vaccines for the Elderly Product Portfolios and Specifications
13.8.3 Sinovac Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Sinovac Main Business Overview
13.8.5 Sinovac Latest Developments
13.9 Kangtai Bio
13.9.1 Kangtai Bio Company Information
13.9.2 Kangtai Bio Vaccines for the Elderly Product Portfolios and Specifications
13.9.3 Kangtai Bio Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Kangtai Bio Main Business Overview
13.9.5 Kangtai Bio Latest Developments
13.10 CDIBP
13.10.1 CDIBP Company Information
13.10.2 CDIBP Vaccines for the Elderly Product Portfolios and Specifications
13.10.3 CDIBP Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 CDIBP Main Business Overview
13.10.5 CDIBP Latest Developments
13.11 Walvax
13.11.1 Walvax Company Information
13.11.2 Walvax Vaccines for the Elderly Product Portfolios and Specifications
13.11.3 Walvax Vaccines for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Walvax Main Business Overview
13.11.5 Walvax Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Vaccines for the Elderly Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Vaccines for the Elderly Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Flu Vaccine
Table 4. Major Players of Respiratory Syncytial Virus (RSV) Vaccine
Table 5. Major Players of Recombinant Herpes Zoster Vaccine
Table 6. Major Players of 23-Valent Pneumococcal Polysaccharide Vaccine
Table 7. Major Players of Others
Table 8. Global Vaccines for the Elderly Sales by Type (2021-2026) & (K Units)
Table 9. Global Vaccines for the Elderly Sales Market Share by Type (2021-2026)
Table 10. Global Vaccines for the Elderly Revenue by Type (2021-2026) & ($ million)
Table 11. Global Vaccines for the Elderly Revenue Market Share by Type (2021-2026)
Table 12. Global Vaccines for the Elderly Sale Price by Type (2021-2026) & (US$/Unit)
Table 13. Global Vaccines for the Elderly Sale by Application (2021-2026) & (K Units)
Table 14. Global Vaccines for the Elderly Sale Market Share by Application (2021-2026)
Table 15. Global Vaccines for the Elderly Revenue by Application (2021-2026) & ($ million)
Table 16. Global Vaccines for the Elderly Revenue Market Share by Application (2021-2026)
Table 17. Global Vaccines for the Elderly Sale Price by Application (2021-2026) & (US$/Unit)
Table 18. Global Vaccines for the Elderly Sales by Company (2021-2026) & (K Units)
Table 19. Global Vaccines for the Elderly Sales Market Share by Company (2021-2026)
Table 20. Global Vaccines for the Elderly Revenue by Company (2021-2026) & ($ millions)
Table 21. Global Vaccines for the Elderly Revenue Market Share by Company (2021-2026)
Table 22. Global Vaccines for the Elderly Sale Price by Company (2021-2026) & (US$/Unit)
Table 23. Key Manufacturers Vaccines for the Elderly Producing Area Distribution and Sales Area
Table 24. Players Vaccines for the Elderly Products Offered
Table 25. Vaccines for the Elderly Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Vaccines for the Elderly Sales by Geographic Region (2021-2026) & (K Units)
Table 29. Global Vaccines for the Elderly Sales Market Share Geographic Region (2021-2026)
Table 30. Global Vaccines for the Elderly Revenue by Geographic Region (2021-2026) & ($ millions)
Table 31. Global Vaccines for the Elderly Revenue Market Share by Geographic Region (2021-2026)
Table 32. Global Vaccines for the Elderly Sales by Country/Region (2021-2026) & (K Units)
Table 33. Global Vaccines for the Elderly Sales Market Share by Country/Region (2021-2026)
Table 34. Global Vaccines for the Elderly Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global Vaccines for the Elderly Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas Vaccines for the Elderly Sales by Country (2021-2026) & (K Units)
Table 37. Americas Vaccines for the Elderly Sales Market Share by Country (2021-2026)
Table 38. Americas Vaccines for the Elderly Revenue by Country (2021-2026) & ($ millions)
Table 39. Americas Vaccines for the Elderly Sales by Type (2021-2026) & (K Units)
Table 40. Americas Vaccines for the Elderly Sales by Application (2021-2026) & (K Units)
Table 41. APAC Vaccines for the Elderly Sales by Region (2021-2026) & (K Units)
Table 42. APAC Vaccines for the Elderly Sales Market Share by Region (2021-2026)
Table 43. APAC Vaccines for the Elderly Revenue by Region (2021-2026) & ($ millions)
Table 44. APAC Vaccines for the Elderly Sales by Type (2021-2026) & (K Units)
Table 45. APAC Vaccines for the Elderly Sales by Application (2021-2026) & (K Units)
Table 46. Europe Vaccines for the Elderly Sales by Country (2021-2026) & (K Units)
Table 47. Europe Vaccines for the Elderly Revenue by Country (2021-2026) & ($ millions)
Table 48. Europe Vaccines for the Elderly Sales by Type (2021-2026) & (K Units)
Table 49. Europe Vaccines for the Elderly Sales by Application (2021-2026) & (K Units)
Table 50. Middle East & Africa Vaccines for the Elderly Sales by Country (2021-2026) & (K Units)
Table 51. Middle East & Africa Vaccines for the Elderly Revenue Market Share by Country (2021-2026)
Table 52. Middle East & Africa Vaccines for the Elderly Sales by Type (2021-2026) & (K Units)
Table 53. Middle East & Africa Vaccines for the Elderly Sales by Application (2021-2026) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities of Vaccines for the Elderly
Table 55. Key Market Challenges & Risks of Vaccines for the Elderly
Table 56. Key Industry Trends of Vaccines for the Elderly
Table 57. Vaccines for the Elderly Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Vaccines for the Elderly Distributors List
Table 60. Vaccines for the Elderly Customer List
Table 61. Global Vaccines for the Elderly Sales Forecast by Region (2027-2032) & (K Units)
Table 62. Global Vaccines for the Elderly Revenue Forecast by Region (2027-2032) & ($ millions)
Table 63. Americas Vaccines for the Elderly Sales Forecast by Country (2027-2032) & (K Units)
Table 64. Americas Vaccines for the Elderly Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 65. APAC Vaccines for the Elderly Sales Forecast by Region (2027-2032) & (K Units)
Table 66. APAC Vaccines for the Elderly Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 67. Europe Vaccines for the Elderly Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Europe Vaccines for the Elderly Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Middle East & Africa Vaccines for the Elderly Sales Forecast by Country (2027-2032) & (K Units)
Table 70. Middle East & Africa Vaccines for the Elderly Revenue Forecast by Country (2027-2032) & ($ millions)
Table 71. Global Vaccines for the Elderly Sales Forecast by Type (2027-2032) & (K Units)
Table 72. Global Vaccines for the Elderly Revenue Forecast by Type (2027-2032) & ($ millions)
Table 73. Global Vaccines for the Elderly Sales Forecast by Application (2027-2032) & (K Units)
Table 74. Global Vaccines for the Elderly Revenue Forecast by Application (2027-2032) & ($ millions)
Table 75. Pfizer Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 76. Pfizer Vaccines for the Elderly Product Portfolios and Specifications
Table 77. Pfizer Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 78. Pfizer Main Business
Table 79. Pfizer Latest Developments
Table 80. GSK Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 81. GSK Vaccines for the Elderly Product Portfolios and Specifications
Table 82. GSK Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 83. GSK Main Business
Table 84. GSK Latest Developments
Table 85. Merck Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 86. Merck Vaccines for the Elderly Product Portfolios and Specifications
Table 87. Merck Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 88. Merck Main Business
Table 89. Merck Latest Developments
Table 90. CSL Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 91. CSL Vaccines for the Elderly Product Portfolios and Specifications
Table 92. CSL Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 93. CSL Main Business
Table 94. CSL Latest Developments
Table 95. Sanofi Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 96. Sanofi Vaccines for the Elderly Product Portfolios and Specifications
Table 97. Sanofi Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. Sanofi Main Business
Table 99. Sanofi Latest Developments
Table 100. AstraZeneca Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 101. AstraZeneca Vaccines for the Elderly Product Portfolios and Specifications
Table 102. AstraZeneca Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 103. AstraZeneca Main Business
Table 104. AstraZeneca Latest Developments
Table 105. Hualan Bio Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 106. Hualan Bio Vaccines for the Elderly Product Portfolios and Specifications
Table 107. Hualan Bio Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 108. Hualan Bio Main Business
Table 109. Hualan Bio Latest Developments
Table 110. Sinovac Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 111. Sinovac Vaccines for the Elderly Product Portfolios and Specifications
Table 112. Sinovac Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 113. Sinovac Main Business
Table 114. Sinovac Latest Developments
Table 115. Kangtai Bio Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 116. Kangtai Bio Vaccines for the Elderly Product Portfolios and Specifications
Table 117. Kangtai Bio Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 118. Kangtai Bio Main Business
Table 119. Kangtai Bio Latest Developments
Table 120. CDIBP Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 121. CDIBP Vaccines for the Elderly Product Portfolios and Specifications
Table 122. CDIBP Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 123. CDIBP Main Business
Table 124. CDIBP Latest Developments
Table 125. Walvax Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 126. Walvax Vaccines for the Elderly Product Portfolios and Specifications
Table 127. Walvax Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 128. Walvax Main Business
Table 129. Walvax Latest Developments
Table 1. Vaccines for the Elderly Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Vaccines for the Elderly Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Flu Vaccine
Table 4. Major Players of Respiratory Syncytial Virus (RSV) Vaccine
Table 5. Major Players of Recombinant Herpes Zoster Vaccine
Table 6. Major Players of 23-Valent Pneumococcal Polysaccharide Vaccine
Table 7. Major Players of Others
Table 8. Global Vaccines for the Elderly Sales by Type (2021-2026) & (K Units)
Table 9. Global Vaccines for the Elderly Sales Market Share by Type (2021-2026)
Table 10. Global Vaccines for the Elderly Revenue by Type (2021-2026) & ($ million)
Table 11. Global Vaccines for the Elderly Revenue Market Share by Type (2021-2026)
Table 12. Global Vaccines for the Elderly Sale Price by Type (2021-2026) & (US$/Unit)
Table 13. Global Vaccines for the Elderly Sale by Application (2021-2026) & (K Units)
Table 14. Global Vaccines for the Elderly Sale Market Share by Application (2021-2026)
Table 15. Global Vaccines for the Elderly Revenue by Application (2021-2026) & ($ million)
Table 16. Global Vaccines for the Elderly Revenue Market Share by Application (2021-2026)
Table 17. Global Vaccines for the Elderly Sale Price by Application (2021-2026) & (US$/Unit)
Table 18. Global Vaccines for the Elderly Sales by Company (2021-2026) & (K Units)
Table 19. Global Vaccines for the Elderly Sales Market Share by Company (2021-2026)
Table 20. Global Vaccines for the Elderly Revenue by Company (2021-2026) & ($ millions)
Table 21. Global Vaccines for the Elderly Revenue Market Share by Company (2021-2026)
Table 22. Global Vaccines for the Elderly Sale Price by Company (2021-2026) & (US$/Unit)
Table 23. Key Manufacturers Vaccines for the Elderly Producing Area Distribution and Sales Area
Table 24. Players Vaccines for the Elderly Products Offered
Table 25. Vaccines for the Elderly Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Vaccines for the Elderly Sales by Geographic Region (2021-2026) & (K Units)
Table 29. Global Vaccines for the Elderly Sales Market Share Geographic Region (2021-2026)
Table 30. Global Vaccines for the Elderly Revenue by Geographic Region (2021-2026) & ($ millions)
Table 31. Global Vaccines for the Elderly Revenue Market Share by Geographic Region (2021-2026)
Table 32. Global Vaccines for the Elderly Sales by Country/Region (2021-2026) & (K Units)
Table 33. Global Vaccines for the Elderly Sales Market Share by Country/Region (2021-2026)
Table 34. Global Vaccines for the Elderly Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global Vaccines for the Elderly Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas Vaccines for the Elderly Sales by Country (2021-2026) & (K Units)
Table 37. Americas Vaccines for the Elderly Sales Market Share by Country (2021-2026)
Table 38. Americas Vaccines for the Elderly Revenue by Country (2021-2026) & ($ millions)
Table 39. Americas Vaccines for the Elderly Sales by Type (2021-2026) & (K Units)
Table 40. Americas Vaccines for the Elderly Sales by Application (2021-2026) & (K Units)
Table 41. APAC Vaccines for the Elderly Sales by Region (2021-2026) & (K Units)
Table 42. APAC Vaccines for the Elderly Sales Market Share by Region (2021-2026)
Table 43. APAC Vaccines for the Elderly Revenue by Region (2021-2026) & ($ millions)
Table 44. APAC Vaccines for the Elderly Sales by Type (2021-2026) & (K Units)
Table 45. APAC Vaccines for the Elderly Sales by Application (2021-2026) & (K Units)
Table 46. Europe Vaccines for the Elderly Sales by Country (2021-2026) & (K Units)
Table 47. Europe Vaccines for the Elderly Revenue by Country (2021-2026) & ($ millions)
Table 48. Europe Vaccines for the Elderly Sales by Type (2021-2026) & (K Units)
Table 49. Europe Vaccines for the Elderly Sales by Application (2021-2026) & (K Units)
Table 50. Middle East & Africa Vaccines for the Elderly Sales by Country (2021-2026) & (K Units)
Table 51. Middle East & Africa Vaccines for the Elderly Revenue Market Share by Country (2021-2026)
Table 52. Middle East & Africa Vaccines for the Elderly Sales by Type (2021-2026) & (K Units)
Table 53. Middle East & Africa Vaccines for the Elderly Sales by Application (2021-2026) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities of Vaccines for the Elderly
Table 55. Key Market Challenges & Risks of Vaccines for the Elderly
Table 56. Key Industry Trends of Vaccines for the Elderly
Table 57. Vaccines for the Elderly Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Vaccines for the Elderly Distributors List
Table 60. Vaccines for the Elderly Customer List
Table 61. Global Vaccines for the Elderly Sales Forecast by Region (2027-2032) & (K Units)
Table 62. Global Vaccines for the Elderly Revenue Forecast by Region (2027-2032) & ($ millions)
Table 63. Americas Vaccines for the Elderly Sales Forecast by Country (2027-2032) & (K Units)
Table 64. Americas Vaccines for the Elderly Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 65. APAC Vaccines for the Elderly Sales Forecast by Region (2027-2032) & (K Units)
Table 66. APAC Vaccines for the Elderly Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 67. Europe Vaccines for the Elderly Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Europe Vaccines for the Elderly Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Middle East & Africa Vaccines for the Elderly Sales Forecast by Country (2027-2032) & (K Units)
Table 70. Middle East & Africa Vaccines for the Elderly Revenue Forecast by Country (2027-2032) & ($ millions)
Table 71. Global Vaccines for the Elderly Sales Forecast by Type (2027-2032) & (K Units)
Table 72. Global Vaccines for the Elderly Revenue Forecast by Type (2027-2032) & ($ millions)
Table 73. Global Vaccines for the Elderly Sales Forecast by Application (2027-2032) & (K Units)
Table 74. Global Vaccines for the Elderly Revenue Forecast by Application (2027-2032) & ($ millions)
Table 75. Pfizer Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 76. Pfizer Vaccines for the Elderly Product Portfolios and Specifications
Table 77. Pfizer Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 78. Pfizer Main Business
Table 79. Pfizer Latest Developments
Table 80. GSK Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 81. GSK Vaccines for the Elderly Product Portfolios and Specifications
Table 82. GSK Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 83. GSK Main Business
Table 84. GSK Latest Developments
Table 85. Merck Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 86. Merck Vaccines for the Elderly Product Portfolios and Specifications
Table 87. Merck Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 88. Merck Main Business
Table 89. Merck Latest Developments
Table 90. CSL Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 91. CSL Vaccines for the Elderly Product Portfolios and Specifications
Table 92. CSL Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 93. CSL Main Business
Table 94. CSL Latest Developments
Table 95. Sanofi Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 96. Sanofi Vaccines for the Elderly Product Portfolios and Specifications
Table 97. Sanofi Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. Sanofi Main Business
Table 99. Sanofi Latest Developments
Table 100. AstraZeneca Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 101. AstraZeneca Vaccines for the Elderly Product Portfolios and Specifications
Table 102. AstraZeneca Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 103. AstraZeneca Main Business
Table 104. AstraZeneca Latest Developments
Table 105. Hualan Bio Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 106. Hualan Bio Vaccines for the Elderly Product Portfolios and Specifications
Table 107. Hualan Bio Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 108. Hualan Bio Main Business
Table 109. Hualan Bio Latest Developments
Table 110. Sinovac Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 111. Sinovac Vaccines for the Elderly Product Portfolios and Specifications
Table 112. Sinovac Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 113. Sinovac Main Business
Table 114. Sinovac Latest Developments
Table 115. Kangtai Bio Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 116. Kangtai Bio Vaccines for the Elderly Product Portfolios and Specifications
Table 117. Kangtai Bio Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 118. Kangtai Bio Main Business
Table 119. Kangtai Bio Latest Developments
Table 120. CDIBP Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 121. CDIBP Vaccines for the Elderly Product Portfolios and Specifications
Table 122. CDIBP Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 123. CDIBP Main Business
Table 124. CDIBP Latest Developments
Table 125. Walvax Basic Information, Vaccines for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 126. Walvax Vaccines for the Elderly Product Portfolios and Specifications
Table 127. Walvax Vaccines for the Elderly Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 128. Walvax Main Business
Table 129. Walvax Latest Developments
LIST OF FIGURES
Figure 1. Picture of Vaccines for the Elderly
Figure 2. Vaccines for the Elderly Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Vaccines for the Elderly Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Vaccines for the Elderly Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Vaccines for the Elderly Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Vaccines for the Elderly Sales Market Share by Country/Region (2025)
Figure 10. Vaccines for the Elderly Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Flu Vaccine
Figure 12. Product Picture of Respiratory Syncytial Virus (RSV) Vaccine
Figure 13. Product Picture of Recombinant Herpes Zoster Vaccine
Figure 14. Product Picture of 23-Valent Pneumococcal Polysaccharide Vaccine
Figure 15. Product Picture of Others
Figure 16. Global Vaccines for the Elderly Sales Market Share by Type in 2026
Figure 17. Global Vaccines for the Elderly Revenue Market Share by Type (2021-2026)
Figure 18. Vaccines for the Elderly Consumed in Hospital
Figure 19. Global Vaccines for the Elderly Market: Hospital (2021-2026) & (K Units)
Figure 20. Vaccines for the Elderly Consumed in Clinic
Figure 21. Global Vaccines for the Elderly Market: Clinic (2021-2026) & (K Units)
Figure 22. Vaccines for the Elderly Consumed in Public Health Agency
Figure 23. Global Vaccines for the Elderly Market: Public Health Agency (2021-2026) & (K Units)
Figure 24. Vaccines for the Elderly Consumed in Others
Figure 25. Global Vaccines for the Elderly Market: Others (2021-2026) & (K Units)
Figure 26. Global Vaccines for the Elderly Sale Market Share by Application (2025)
Figure 27. Global Vaccines for the Elderly Revenue Market Share by Application in 2026
Figure 28. Vaccines for the Elderly Sales by Company in 2026 (K Units)
Figure 29. Global Vaccines for the Elderly Sales Market Share by Company in 2026
Figure 30. Vaccines for the Elderly Revenue by Company in 2026 ($ millions)
Figure 31. Global Vaccines for the Elderly Revenue Market Share by Company in 2026
Figure 32. Global Vaccines for the Elderly Sales Market Share by Geographic Region (2021-2026)
Figure 33. Global Vaccines for the Elderly Revenue Market Share by Geographic Region in 2026
Figure 34. Americas Vaccines for the Elderly Sales 2021-2026 (K Units)
Figure 35. Americas Vaccines for the Elderly Revenue 2021-2026 ($ millions)
Figure 36. APAC Vaccines for the Elderly Sales 2021-2026 (K Units)
Figure 37. APAC Vaccines for the Elderly Revenue 2021-2026 ($ millions)
Figure 38. Europe Vaccines for the Elderly Sales 2021-2026 (K Units)
Figure 39. Europe Vaccines for the Elderly Revenue 2021-2026 ($ millions)
Figure 40. Middle East & Africa Vaccines for the Elderly Sales 2021-2026 (K Units)
Figure 41. Middle East & Africa Vaccines for the Elderly Revenue 2021-2026 ($ millions)
Figure 42. Americas Vaccines for the Elderly Sales Market Share by Country in 2026
Figure 43. Americas Vaccines for the Elderly Revenue Market Share by Country (2021-2026)
Figure 44. Americas Vaccines for the Elderly Sales Market Share by Type (2021-2026)
Figure 45. Americas Vaccines for the Elderly Sales Market Share by Application (2021-2026)
Figure 46. United States Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 47. Canada Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 48. Mexico Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 49. Brazil Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 50. APAC Vaccines for the Elderly Sales Market Share by Region in 2026
Figure 51. APAC Vaccines for the Elderly Revenue Market Share by Region (2021-2026)
Figure 52. APAC Vaccines for the Elderly Sales Market Share by Type (2021-2026)
Figure 53. APAC Vaccines for the Elderly Sales Market Share by Application (2021-2026)
Figure 54. China Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 55. Japan Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 56. South Korea Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 57. Southeast Asia Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 58. India Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 59. Australia Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 60. China Taiwan Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 61. Europe Vaccines for the Elderly Sales Market Share by Country in 2026
Figure 62. Europe Vaccines for the Elderly Revenue Market Share by Country (2021-2026)
Figure 63. Europe Vaccines for the Elderly Sales Market Share by Type (2021-2026)
Figure 64. Europe Vaccines for the Elderly Sales Market Share by Application (2021-2026)
Figure 65. Germany Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 66. France Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 67. UK Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 68. Italy Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 69. Russia Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 70. Middle East & Africa Vaccines for the Elderly Sales Market Share by Country (2021-2026)
Figure 71. Middle East & Africa Vaccines for the Elderly Sales Market Share by Type (2021-2026)
Figure 72. Middle East & Africa Vaccines for the Elderly Sales Market Share by Application (2021-2026)
Figure 73. Egypt Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 74. South Africa Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 75. Israel Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 76. Turkey Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 77. GCC Countries Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 78. Manufacturing Cost Structure Analysis of Vaccines for the Elderly in 2026
Figure 79. Manufacturing Process Analysis of Vaccines for the Elderly
Figure 80. Industry Chain Structure of Vaccines for the Elderly
Figure 81. Channels of Distribution
Figure 82. Global Vaccines for the Elderly Sales Market Forecast by Region (2027-2032)
Figure 83. Global Vaccines for the Elderly Revenue Market Share Forecast by Region (2027-2032)
Figure 84. Global Vaccines for the Elderly Sales Market Share Forecast by Type (2027-2032)
Figure 85. Global Vaccines for the Elderly Revenue Market Share Forecast by Type (2027-2032)
Figure 86. Global Vaccines for the Elderly Sales Market Share Forecast by Application (2027-2032)
Figure 87. Global Vaccines for the Elderly Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Vaccines for the Elderly
Figure 2. Vaccines for the Elderly Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Vaccines for the Elderly Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Vaccines for the Elderly Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Vaccines for the Elderly Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Vaccines for the Elderly Sales Market Share by Country/Region (2025)
Figure 10. Vaccines for the Elderly Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Flu Vaccine
Figure 12. Product Picture of Respiratory Syncytial Virus (RSV) Vaccine
Figure 13. Product Picture of Recombinant Herpes Zoster Vaccine
Figure 14. Product Picture of 23-Valent Pneumococcal Polysaccharide Vaccine
Figure 15. Product Picture of Others
Figure 16. Global Vaccines for the Elderly Sales Market Share by Type in 2026
Figure 17. Global Vaccines for the Elderly Revenue Market Share by Type (2021-2026)
Figure 18. Vaccines for the Elderly Consumed in Hospital
Figure 19. Global Vaccines for the Elderly Market: Hospital (2021-2026) & (K Units)
Figure 20. Vaccines for the Elderly Consumed in Clinic
Figure 21. Global Vaccines for the Elderly Market: Clinic (2021-2026) & (K Units)
Figure 22. Vaccines for the Elderly Consumed in Public Health Agency
Figure 23. Global Vaccines for the Elderly Market: Public Health Agency (2021-2026) & (K Units)
Figure 24. Vaccines for the Elderly Consumed in Others
Figure 25. Global Vaccines for the Elderly Market: Others (2021-2026) & (K Units)
Figure 26. Global Vaccines for the Elderly Sale Market Share by Application (2025)
Figure 27. Global Vaccines for the Elderly Revenue Market Share by Application in 2026
Figure 28. Vaccines for the Elderly Sales by Company in 2026 (K Units)
Figure 29. Global Vaccines for the Elderly Sales Market Share by Company in 2026
Figure 30. Vaccines for the Elderly Revenue by Company in 2026 ($ millions)
Figure 31. Global Vaccines for the Elderly Revenue Market Share by Company in 2026
Figure 32. Global Vaccines for the Elderly Sales Market Share by Geographic Region (2021-2026)
Figure 33. Global Vaccines for the Elderly Revenue Market Share by Geographic Region in 2026
Figure 34. Americas Vaccines for the Elderly Sales 2021-2026 (K Units)
Figure 35. Americas Vaccines for the Elderly Revenue 2021-2026 ($ millions)
Figure 36. APAC Vaccines for the Elderly Sales 2021-2026 (K Units)
Figure 37. APAC Vaccines for the Elderly Revenue 2021-2026 ($ millions)
Figure 38. Europe Vaccines for the Elderly Sales 2021-2026 (K Units)
Figure 39. Europe Vaccines for the Elderly Revenue 2021-2026 ($ millions)
Figure 40. Middle East & Africa Vaccines for the Elderly Sales 2021-2026 (K Units)
Figure 41. Middle East & Africa Vaccines for the Elderly Revenue 2021-2026 ($ millions)
Figure 42. Americas Vaccines for the Elderly Sales Market Share by Country in 2026
Figure 43. Americas Vaccines for the Elderly Revenue Market Share by Country (2021-2026)
Figure 44. Americas Vaccines for the Elderly Sales Market Share by Type (2021-2026)
Figure 45. Americas Vaccines for the Elderly Sales Market Share by Application (2021-2026)
Figure 46. United States Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 47. Canada Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 48. Mexico Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 49. Brazil Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 50. APAC Vaccines for the Elderly Sales Market Share by Region in 2026
Figure 51. APAC Vaccines for the Elderly Revenue Market Share by Region (2021-2026)
Figure 52. APAC Vaccines for the Elderly Sales Market Share by Type (2021-2026)
Figure 53. APAC Vaccines for the Elderly Sales Market Share by Application (2021-2026)
Figure 54. China Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 55. Japan Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 56. South Korea Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 57. Southeast Asia Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 58. India Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 59. Australia Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 60. China Taiwan Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 61. Europe Vaccines for the Elderly Sales Market Share by Country in 2026
Figure 62. Europe Vaccines for the Elderly Revenue Market Share by Country (2021-2026)
Figure 63. Europe Vaccines for the Elderly Sales Market Share by Type (2021-2026)
Figure 64. Europe Vaccines for the Elderly Sales Market Share by Application (2021-2026)
Figure 65. Germany Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 66. France Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 67. UK Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 68. Italy Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 69. Russia Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 70. Middle East & Africa Vaccines for the Elderly Sales Market Share by Country (2021-2026)
Figure 71. Middle East & Africa Vaccines for the Elderly Sales Market Share by Type (2021-2026)
Figure 72. Middle East & Africa Vaccines for the Elderly Sales Market Share by Application (2021-2026)
Figure 73. Egypt Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 74. South Africa Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 75. Israel Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 76. Turkey Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 77. GCC Countries Vaccines for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 78. Manufacturing Cost Structure Analysis of Vaccines for the Elderly in 2026
Figure 79. Manufacturing Process Analysis of Vaccines for the Elderly
Figure 80. Industry Chain Structure of Vaccines for the Elderly
Figure 81. Channels of Distribution
Figure 82. Global Vaccines for the Elderly Sales Market Forecast by Region (2027-2032)
Figure 83. Global Vaccines for the Elderly Revenue Market Share Forecast by Region (2027-2032)
Figure 84. Global Vaccines for the Elderly Sales Market Share Forecast by Type (2027-2032)
Figure 85. Global Vaccines for the Elderly Revenue Market Share Forecast by Type (2027-2032)
Figure 86. Global Vaccines for the Elderly Sales Market Share Forecast by Application (2027-2032)
Figure 87. Global Vaccines for the Elderly Revenue Market Share Forecast by Application (2027-2032)
